Oculis Holding AG (OCS) Cash & Current Investments (2020 - 2026)
Oculis Holding AG (OCS) posted quarterly Cash & Current Investments of $283.5 million for Q1 2026, up 40.12% year-over-year from $202.3 million in Q1 2025, and up 6.39% quarter-over-quarter from $266.5 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Cash & Current Investments (2020 - 2026) Analysis & Trends
Oculis Holding AG's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $283.5 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 40.12% year-over-year to $283.5 million; the TTM figure through Mar 2026 stood at $283.5 million (up 40.12% YoY), while the FY2025 annual figure was $256.9 million, up 129.09% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $283.5 million, up from $266.5 million in the prior quarter.
- The five-year high for Cash & Current Investments was $283.5 million in Q1 2026, with the low at -$51.1 million in Q3 2023.
- The 5-year median for Cash & Current Investments is $121.7 million (2024), against an average of $115.5 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments slumped 186.92% in 2023, then jumped 730.86% in 2024.
- Oculis Holding AG's Cash & Current Investments stood at $20.5 million in 2022, then slumped by 186.92% to -$17.9 million in 2023, then surged by 730.86% to $112.6 million in 2024, then jumped by 136.64% to $266.5 million in 2025, then climbed by 6.39% to $283.5 million in 2026.
- Business Quant data shows OCS's Cash & Current Investments at $283.5 million in Q1 2026, $266.5 million in Q4 2025, and $181.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 288.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 288.88 Mn |
| Mar 31, 2026 | 283.54 Mn |
| Dec 31, 2025 | 266.52 Mn |
| Sep 30, 2025 | 181.49 Mn |
| Jun 30, 2025 | 193.62 Mn |
| Mar 31, 2025 | 202.35 Mn |
| Dec 31, 2024 | 112.63 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Jun 30, 2024 | 130.40 Mn |
| Mar 31, 2024 | 91.58 Mn |
| Dec 31, 2023 | -17.85 Mn |
| Sep 30, 2023 | -51.11 Mn |
| Jun 30, 2023 | -33.53 Mn |
| Dec 31, 2022 | 20.59 Mn |
| Dec 31, 2021 | 50.24 Mn |
| Dec 31, 2020 | 5.48 Mn |